In Vivo delivery of morpholino oligos by cell-penetrating peptides

Current Pharmaceutical Design

Volumn 19, Issue 16, 2013, Pages 2963-2969

  Moulton, Hong M ^a  

^a OREGON STATE UNIVERSITY   (United States)

Author keywords

Antisense; Cell penetrating peptide; Duchenne muscular dystrophy; Morpholino oligos; PPMO

Indexed keywords

CELL PENETRATING PEPTIDE; DYSTROPHIN; MORPHOLINO OLIGONUCLEOTIDE;

AMINO ACID SEQUENCE; ARTICLE; BECKER MUSCULAR DYSTROPHY; CLINICAL TRIAL (TOPIC); CREATINE KINASE BLOOD LEVEL; DISSOCIATION CONSTANT; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; EXON SKIPPING; GENE FUNCTION; GENE SILENCING; GRIP STRENGTH; HEART FUNCTION; HUMAN; HUMORAL IMMUNITY; IN VIVO STUDY; INNATE IMMUNITY; INTERNALIZATION; MUSCLE ATROPHY; MUSCULAR DYSTROPHY; NONSENSE MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN RNA BINDING; SURFACE PLASMON RESONANCE; SYSTOLIC BLOOD PRESSURE; TISSUE DISTRIBUTION; TREADMILL EXERCISE;

ANIMALS; BIOTERRORISM; CELL-PENETRATING PEPTIDES; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; GENE KNOCKDOWN TECHNIQUES; HUMANS; MARBURG VIRUS DISEASE; MORPHOLINOS; MUSCULAR DYSTROPHY, DUCHENNE; TISSUE DISTRIBUTION;

EID: 84878668264     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319160010     Document Type: Article

References (73)

1. Summerton J, Weller D. Morpholino antisense oligomers: design, preparation, and properties, Antisense Nucleic Acid Drug Dev 1997; 7: 187-95.
2. Hudziak RM, Barofsky E, Barofsky DF, Weller DL, Huang SB, Weller DD. Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation, Antisense Nucleic Acid Drug Dev 1996; 6: 267-72.
3. Youngblood DS, Hatlevig SA, Hassinger JN, Iversen PL, Moulton HM. Stability of cell-penetrating peptide-morpholino oligomer conjugates in human serum and in cells, Bioconjug Chem 2007; 18: 50-60.
4. Amantana A, Moulton HM, Cate ML, et al. Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptidemorpholino oligomer conjugate, Bioconjug Chem 2007; 18: 1325-31.
5. Summerton J. Morpholino antisense oligomers: the case for an RNase H-independent structural type, Biochim Biophys Acta 1999; 1489: 141-58.
6. Summerton JE. Morpholino, siRNA, and S-DNA compared: impact of structure and mechanism of action on off-target effects and sequence specificity, Curr Top Med Chem 2007; 7: 651-60.
7. Hudziak RM, Summerton J, Weller DD, Iversen PL. Antiproliferative effects of steric blocking phosphorodiamidate morpholino antisense agents directed against c-myc, Antisense Nucleic Acid Drug Dev 2000; 10: 163-76.
8. Alter J, Lou F, Rabinowitz A, et al. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology, Nat Med 2006; 12: 175-7.
9. Kloosterman WP, Lagendijk AK, Ketting RF, Moulton JD, Plasterk RH. Targeted inhibition of miRNA maturation with morpholinos reveals a role for miR-375 in pancreatic islet development, PLoS Biol 2007; 5: e203.
10. Bruno IG, Jin W, Cote GJ. Correction of aberrant FGFR1 alternative RNA splicing through targeting of intronic regulatory elements, Hum Mol Genet 2004; 13: 2409-20.
11. Yen L, Svendsen J, Lee JS, et al. Exogenous control of mammalian gene expression through modulation of RNA self-cleavage, Nature 2004; 431: 471-6.
12. Arthur PK, Claussen M, Koch S, Tarbashevich K, Jahn O, Pieler T. Participation of Xenopus Elr-type proteins in vegetal mRNA localization during oogenesis, J Biol Chem 2009; 284: 19982-92.
13. Howard MT, Gesteland RF, Atkins JF. Efficient stimulation of sitespecific ribosome frameshifting by antisense oligonucleotides, RNA 2004; 10: 1653-61.
14. Bill BR, Petzold AM, Clark KJ, Schimmenti LA, Ekker SC. A primer for morpholino use in zebrafish, Zebrafish 2009; 6: 69-77.
15. Mimoto MS, Christian JL. Manipulation of gene function in Xenopus laevis, Methods Mol Biol 770 55-75.
16. Wei Z, Angerer RC, Angerer LM. Direct development of neurons within foregut endoderm of sea urchin embryos, Proc Natl Acad Sci USA 2011; 108: 9143-7.
17. Christiaen L, Wagner E, Shi W, Levine M. Microinjection of morpholino oligos and RNAs in sea squirt (Ciona) embryos, Cold Spring Harb Protoc 2009; 2009: pdb prot5347.
18. Yin H, Moulton HM, Seow Y, Boyd C, Boutilier J, Iverson P, Wood MJ. Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function, Hum Mol Genet 2008; 17: 3909-18.
19. Eisen JS, Smith JC, Controlling morpholino experiments: don't stop making antisense, Development 2008; 135: 1735-43.
20. Moulton JD, Yan YL, Using Morpholinos to control gene expression, Curr Protoc Mol Biol Chapter 2008; 26: Unit 26 28.
21. Sazani P, Ness KP, Weller DL, Poage D, Nelson K, Shrewsbury AS. Chemical and mechanistic toxicology evaluation of exon skipping phosphorodiamidate morpholino oligomers in mdx mice, Int J Toxicol 2011; 30: 322-33.
22. Sazani P, Ness K. P, Weller D. L, Poage D. W, Palyada K, Shrewsbury SB. Repeat-dose toxicology evaluation in cynomolgus monkeys of AVI-4658, a phosphorodiamidate morpholino oligomer (PMO) drug for the treatment of duchenne muscular dystrophy, Int J Toxicol 2011; 30: 313-21.
23. Sazani P, Weller D. L, Shrewsbury SB. Safety pharmacology and genotoxicity evaluation of AVI-4658, Int J Toxicol 2010; 29: 143-56.
24. Wu B, Xiao B, Cloer C, et al. One-year treatment of morpholino antisense oligomer improves skeletal and cardiac muscle functions in dystrophic mdx mice, Mol Ther 2010; 19: 576-83.
25. Cirak S, Feng L, Anthony K, et al. Restoration of the dystrophinassociated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophy, Mol Ther 2011; 20: 462-7.
26. Kinali M, Arechavala-Gomeza V, Feng L, et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebocontrolled, dose-escalation, proof-of-concept study, Lancet Neurol 2009; 8: 918-28.
27. Moulton HM, Moulton JD. Peptide-assisted delivery of stericblocking antisense oligomers, Curr Opin Mol Ther 2003; 5: 123-32.
28. Moulton HM, Moulton JD. Arginine-rich cell-penetrating peptides with uncharged antisense oligomers, Drug Discov Today 2004; 9: 870.
29. Moulton HM, Moulton JD. Morpholinos and their peptide conjugates: Therapeutic promise and challenge for Duchenne muscular dystrophy, Biochim Biophys Acta (2010).
30. Moulton HM, Nelson MH, Hatlevig SA, Reddy MT, Iversen PL. Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides, Bioconjug Chem 2004; 15: 290-9.
31. Neuman BW, Stein DA, Kroeker AD, et al. Inhibition and escape of SARS-CoV treated with antisense morpholino oligomers, Adv Exp Med Biol 2006; 581: 567-71.
32. Svasti S, Suwanmanee T, Fucharoen S, et al. RNA repair restores hemoglobin expression in IVS2-654 thalassemic mice, Proc Natl Acad Sci USA 2009; 106: 1205-10.
33. Swenson DL, Warfield KL, Warren TK, et al. Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection, Antimicrob Agents Chemother 2009; 53: 2089-99.
34. Wu B, Moulton HM, Iversen PL, et al. Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer, Proc Natl Acad Sci USA 2008; 105: 14814-9.
35. Wu RP, Youngblood DS, Hassinger JN, et al. Cell-penetrating peptides as transporters for morpholino oligomers: effects of amino acid composition on intracellular delivery and cytotoxicity, Nucleic Acids Res 2007; 35: 5182-91.
36. Li YF, Morcos PA. Design and synthesis of dendritic molecular transporter that achieves efficient in vivo delivery of morpholino antisense oligo, Bioconjug Chem 2008; 19: 1464-70.
37. Moulton HM, Hase MC, Smith KM, Iversen PL. HIV Tat peptide enhances cellular delivery of antisense morpholino oligomers, Antisense Nucleic Acid Drug Dev 2003; 13: 31-43.
38. Pillai VC, Yesudas R, Shaik IH, et al. Delivery of NADPHcytochrome P450 reductase antisense oligos using avidin-biotin approach, Bioconjug Chem 2010; 21: 203-7.
39. Summerton J. E, Endo-Porter: a novel reagent for safe, effective delivery of substances into cells, Ann N Y Acad Sci 2005; 1058: 62-75.
40. Nikopoulos GN, Adams TL, Adams D, Oxburgh L, Prudovsky I, Verdi JM. The use of Endo-Porter to deliver morpholinos in kidney organ culture, Biotechniques 2008; 44: 547-9.
41. Abes S, Moulton HM, Clair P, et al. Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents, J Control Release 2006; 116: 304-13.
42. Jearawiriyapaisarn N, Moulton HM, Buckley B, et al. Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice, Mol Ther 2008; 16: 1624-9.
43. Enterlein S, Warfield KL, Swenson DL, et al. VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice, Antimicrob Agents Chemother 2006; 50: 984-93.
44. Holden KL, Stein DA, Pierson TC, et al. Inhibition of dengue virus translation and RNA synthesis by a morpholino oligomer targeted to the top of the terminal 3' stem-loop structure, Virology 2006; 344: 439-52.
45. Nelson MH, Stein DA, Kroeker AD, Hatlevig SA, Iversen PL, Moulton HM. Arginine-rich peptide conjugation to morpholino oligomers: effects on antisense activity and specificity, Bioconjug Chem 2005; 16: 959-66.
46. Zhang YJ, Wang KY, Stein DA, et al. Inhibition of replication and transcription activator and latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus by morpholino oligomers, Antiviral Res 2007; 73: 12-23.
47. Deas TS, Bennett CJ, Jones SA, et al. In vitro resistance selection and in vivo efficacy of morpholino oligomers against West Nile virus, Antimicrob Agents Chemother 2007; 51: 2470-82.
48. Deas TS, Binduga-Gajewska I, Tilgner M, et al. Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication, J Virol 2005; 79: 4599-609.
49. Ge Q, Pastey M, Kobasa D, et al. Inhibition of multiple subtypes of influenza A virus in cell cultures with morpholino oligomers, Antimicrob Agents Chemother 2006; 50: 3724-33.
50. Kinney RM, Huang CY, Rose BC, et al. Inhibition of dengue virus serotypes 1 to 4 in vero cell cultures with morpholino oligomers, J Virol 2005; 79: 5116-28.
51. Yuan J, Stein DA, Lim T, et al. Inhibition of coxsackievirus B3 in cell cultures and in mice by peptide-conjugated morpholino oligomers targeting the internal ribosome entry site, J Virol 2006; 80: 11510-9.
52. Burrer R, Neuman BW, Ting JP, et al. Antiviral effects of antisense morpholino oligomers in murine coronavirus infection models, J Virol 2007; 81: 5637-48.
53. Gabriel G, Nordmann A, Stein DA, Iversen PL, Klenk HD. Morpholino oligomers targeting the PB1 and NP genes enhance the survival of mice infected with highly pathogenic influenza A H7N7 virus, J Gen Virol 2008; 89: 939-48.
54. Lupfer C, Stein DA, Mourich DV, Tepper SE, Iversen PL, Pastey M. Inhibition of influenza A H3N8 virus infections in mice by morpholino oligomers, Arch Virol 2008; 153: 929-37.
55. Lai SH, Stein DA, Guerrero-Plata A, et al. Inhibition of respiratory syncytial virus infections with morpholino oligomers in cell cultures and in mice, Mol Ther 2008; 16: 1120-8.
56. Opriessnig T, Patel D, Wang R, et al. Inhibition of porcine reproductive and respiratory syndrome virus infection in piglets by a peptide-conjugated morpholino oligomer, Antiviral Res 2011; 91: 36-42.
57. Eide K, Moerdyk-Schauwecker M, Stein DA, Bildfell R, Koelle DM, Jin L. Reduction of herpes simplex virus type-2 replication in cell cultures and in rodent models with peptide-conjugated morpholino oligomers, Antivir Ther 2010; 15: 1141-9.
58. Moerdyk-Schauwecker M, Stein DA, Eide K, et al. Inhibition of HSV-1 ocular infection with morpholino oligomers targeting ICP0 and ICP27, Antiviral Res 2009; 84: 131-41.
59. Neuman BW, Stein DA, Kroeker AD, et al. Buchmeier, Inhibition, escape, and attenuated growth of severe acute respiratory syndrome coronavirus treated with antisense morpholino oligomers, J Virol 2005; 79: 9665-76.
60. Stein DA. Inhibition of RNA virus infections with peptideconjugated morpholino oligomers, Curr Pharm Des 2008; 14: 2619-34.
61. Greenberg DE, Marshall-Batty KR, Brinster LR, et al, Antisense phosphorodiamidate morpholino oligomers targeted to an essential gene inhibit Burkholderia cepacia complex, J Infect Dis 2010; 201: 1822-30.
62. Mellbye BL, Puckett SE, Tilley LD, Iversen PL, Geller BL. Variations in amino acid composition of antisense peptidephosphorodiamidate morpholino oligomer affect potency against Escherichia coli in vitro and in vivo, Antimicrob Agents Chemother 2009; 53: 525-30.
63. Fletcher S, Honeyman K, Fall AM, Harding PL, Johnsen RD, Wilton SD. Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide, J Gene Med 2006; 8: 207-16.
64. Malerba A, Thorogood FC, Dickson G, Graham IR. Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx mice, Hum Gene Ther 2009; 20: 955-65.
65. Yin H, Saleh AF, Betts C, et al. Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice, Mol Ther 2011; 19: 1295-303.
66. Moulton HM, Moulton JD. Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy, Biochim Biophys Acta 2010; 1798: 2296-303.
67. Yokota T, Lu QL, Partridge T, Kobayashi M, Nakamura A, Takeda S. Hoffman E, Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs, Ann Neurol 2009; 65: 667-76.
68. Jearawiriyapaisarn N, Moulton HM, Sazani P, Kole R, Willis MS. Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers, Cardiovasc Res 2010; 85: 444-53.
69. Wu B, Lu P, Cloer C, et al. Long-term rescue of dystrophin expression and improvement in muscle pathology and function in dystrophic mdx mice by peptide-conjugated morpholino, Am J Pathol 2012; 181: 392-400.
70. Sazani P, Blouch R, Weller D, Leow S, Kole R, Shrewsburry S. AVI 5038: Initail Efficacy and Safety Evaluation in Cynomolgus Monkeys, Treat-NMD/NIH Conference 2009, Brussels, Belgium, 2009.
71. Yin H, Moulton HM, Betts C, et al. A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice, Hum Mol Genet 2009; 18: 4405-14.
72. Sazani P, Gemignani F, Kang S. H, et al. Systemically delivered antisense oligomers upregulate gene expression in mouse tissues, Nat Biotechnol 2002; 20: 1228-33.
73. Yin H, Moulton HM, Betts C, et al. Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO, Mol Ther 2010; 18: 1822-9